MEDraysintell Publishes the 9th Edition of Its Nuclear Medicine Report & Directory

A set of three volumes (3,500 pages) with a description of 970 products, together with a comprehensive profile of 380 companies active around the world in the radiopharmaceutical industry. - September 16, 2022

MEDraysintell Publishes the 8th Edition of Its Nuclear Medicine Report & Directory

A set of three volumes (3,100 pages) with a description of 870 products, together with a comprehensive profile of 340 companies active around the world in the radiopharmaceutical industry. - September 16, 2021

MEDraysintell Publishes Its New Proton Therapy World Report & Directory, Edition 2021

Proton therapy market headwinds: demand down, supply up, but increasing awareness. - March 06, 2021

MEDraysintell Welcomes Jean-Luc Vanderheyden as Advisor

Jean-Luc Vanderheyden joins MEDraysintell as Advisor and brings his extended experience (35 years) in the field of nuclear medicine. Jean-Luc is a Doctor of Pharmacy and PhD Analytical Chemist (Université Libre de Bruxelles and University of Cincinnati), with a strong expertise in... - September 05, 2020

MEDraysintell Publishes Its New Nuclear Medicine Report and Directory

A set of three volumes (2,900 pages) with a description of about 830 products and nearly 320 companies active in nuclear medicine. - September 02, 2020

MEDraysintell Releases the Most Unique Cyclotron Directory

A 450-page report which provides an extensive review of all cyclotrons installed worldwide. - March 11, 2020

MEDraysintell Releases Its New Early Stage Radiopharmaceuticals Report

In addition to its original Nuclear Medicine Report - July 12, 2019

MEDraysintell Publishes Its Sixth Edition of the Proton Therapy World Report & Directory

What to Expect from the Proton Therapy Market in 2019-2020? - February 21, 2019

MEDraysintell Anticipates Increasing M&A Activities in Nuclear Medicine

Some US$10 billion in M&A transactions during the past four years. - November 08, 2018

MEDraysintell to Showcase Its Reports at EANM in Düsseldorf

MEDraysintell will be present on The Belgian Pavilion booth-14. - October 04, 2018

MEDraysintell Releases the Fifth Edition of Its Nuclear Medicine Report and Directory

New radiotheranostics under development might lead to much stronger market figures than expected in coming years. - July 18, 2018

Serge Goossens Joins MEDraysintell as Co-Author & Advisor

A new report and directory about radioactive material transport and handling under preparation. - June 20, 2018

MEDraysintell Releases a New Report Covering the Most Promising Radiopharmaceuticals

Most promising radiopharmaceuticals on the market by 2024-2026 - February 03, 2018

MEDraysintell Releases Its New Proton Therapy World Market Report & Directory Edition 2018

The top three vendors share now 70% of the PT market in 2017 valued at US$ 0.9 billion. Several companies are expected to enter the market for the first time in the coming years with their own PT systems. - January 19, 2018

MEDraysintell Downgrades Its Proton Therapy Market Projection

In light of several factors summarized below, MEDraysintell is downgrading its proton therapy market projection from 1,200 proton therapy treatment rooms that were expected to be operational in 2030 to 900. This still represents a 12% annual growth from 2017 to 2030 and the need to open an average... - December 02, 2017

MEDraysintell Will Display Its Series of Market Reports at EANM Congress in Vienna

Need to understand future and economics of Nuclear Medicine? Looking for experts in this field? Trying to appreciate the potential of this new technology? - October 11, 2017

MEDraysintell Releases Its First Nuclear Medicine Market Essentials Report

A condensed report, with over 40 tables and figures, providing the most accurate and up-to-date information related to the nuclear medicine industry. - January 20, 2017

Brachytherapy Market Driven by New Technologies and New Indications

The global market for brachytherapy reached US$ 680 million in 2013, and the trend is toward a growth driven by new technologies (electronic brachytherapy, microspheres), new indications for LDR (lung, liver) and new markets (Asia, South America). - November 14, 2014

Press Releases 1 - 18 of 18